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Hereditary medullary thyroid cancer is an aggressive cancer for which there is no standard eﬀective systemic therapy, but which
can be prevented through genetic screening and prophylactic thyroidectomy. Although this cancer accounts for roughly 17% of
all pediatric thyroid cancers, a significant percentage of aﬀected families do not “accept” screening, while many gene carriers
delay or refuse prophylactic thyroid surgery for their children. Current genetic screening practices in medullary thyroid cancer are
inadequate; more than 50% of index patients with hereditary medullary thyroid cancer present with a thyroid mass; up to 75%
have distant metastasis. These proposed pediatric ethics guidelines focus on two ethical issues that aﬀect at-risk children: (1) how
do we identify at-risk children whose RET-positive relative refuses to disclose that they carry the mutation? (2) How do we protect
RET-positive children whose parents refuse prophylactic thyroidectomy?

1. Introduction
Medullary thyroid cancer (MTC) is an uncommon type of
aggressive thyroid cancer that does not respond to systemic
radioactive iodine, an eﬀective treatment for most other
types of thyroid cancer. This cancer’s aggressive biological
behavior also diminishes the eﬀectiveness of surgical therapy,
and there is currently no standard eﬀective chemotherapy for
this cancer.
The etiology of MTC is well documented in the literature;
it may occur sporadically or present as part of an autosomal
dominant inherited disorder. If inherited, MTC is 100%
penetrant [1], although the age of onset is variable [1–5]. In
1993, germline mutations in the RET proto-oncogene were
found to be responsible for hereditary MTC [3], allowing
genetic testing to be used as the primary tool for detecting
its presence in at-risk family members. We use the term
hereditary medullary thyroid cancer to discuss both familial
medullary thyroid cancer (FMTC) and medullary thyroid
cancer arising from MEN 2 syndromes (MEN 2A and MEN
2B). In the general population, MTC accounts for 5%–8%

percent of all thyroid cancers [6–8] and about 15% of all
thyroid cancer-related deaths [6]. However, the published
statistics on this type of cancer are based on narrow studies
and a small literature; the true incidence and prevalence of
MTC is likely much higher than what has been reported.
According to 2009 SEER data available from the National
Cancer Institute, we estimate the national incidence rate of
MTC to be approximately 3000 new index cases per year,
with a national prevalence of roughly 35,000. Since MTC can
be either inherited (familial or hereditary) or not inherited
(sporadic), it is also standard of care to oﬀer all index
patients genetic testing to rule out the genetic mutation for
the inherited form. If an index patient decides not to get
tested, he or she may unknowingly represent a large kindred
comprising dozens, or hundreds, of at-risk individuals who
may eventually die from this cancer because the opportunity
for genetic screening and prophylactic surgery was missed.
Family members of positive probands will develop medullary
thyroid cancer if they, too, test positive for the mutation [1].
Roughly 25%–30% of known MTC cases are hereditary
[1, 4, 6, 8]. The reported incidence and prevalence rates
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significantly underestimate the number of hereditary cases,
since it does not account for undiagnosed cases in unreported kindreds. It also does not account for the many
people who have the gene mutation for MTC, but have
not yet developed this cancer. Surgery represents the only
eﬀective curative treatment [9], but must occur before the
cancer has spread beyond the thyroid gland. This provides
the rationale for identifying MTC early through screening. In
the absence of early identification through genetic screening,
MTC typically presents in a later stage, often as metastatic
disease for which there is no eﬀective curative treatment.
Chemotherapy and external beam radiation therapy are
typically only palliative or ineﬀective in treating unresectable
metastatic MTC.
In the pediatric population, MTC represents 17% of all
childhood thyroid cancers [3], and in children who test
positive for the gene (and therefore identified as having
hereditary MTC), the American Thyroid Association recommends thyroidectomy at the following age intervals [4]:
ages 0-1 for RET mutations that carry the highest risk for
aggressive MTC at young ages, classified as “ATA-D”; before
the age of five for RET mutations that carry a high risk of
aggressive MTC at any age, classified as “ATA-C”; beyond
the age of 5 for RET mutations that carry a lower risk of
aggressive MTC classified as “ATA-B” or “ATA-A,” so long as
the child has been carefully evaluated and monitored, and
there are no other clinical signs that suggest that MTC has
developed.
1.1. Genetic Testing. RET genetic mutation testing has been
shown to be more sensitive than traditional biochemical
screening. In one of the first studies to establish the role
of genetic testing, which involved 300 members of four
large kindreds, 14 young individuals with RET mutations
had normal plasma calcitonin levels, while thyroidectomy
revealed small foci of MTC in all eight of these 14 individuals
who agreed to undergo surgery [5]. Germline RET mutations
have been observed in 3%–9% of MTC patients with no
family history of MTC [10–12] indicating that a significant
number of apparently sporadic cases of MTC are due
to occult or de novo germline RET mutations. As time
progresses, more sites of potential mutation in the RET
proto-oncogene have been associated with hereditary MTC,
resulting in genetic analysis of progressively more exons and
suggesting that the rate of unsuspected familial cases is likely
much higher. Genetic testing for hereditary MTC syndromes
has had an enormous impact on reducing the burden of this
disease for families [2] and has the potential to dramatically
reduce the incidence of MTC when it occurs as part of these
hereditary syndromes.
Since the discovery of RET mutations, and the availability
of genetic testing and screening for these mutations, the
vast majority of literature published in this area [2, 3, 13–
41] acknowledges the value of genetic screening in at-risk
family members and prophylactic thyroidectomy in those
who test positive [13, 42]. The current standard of care is
to recommend genetic testing for all at-risk family members
of the positive proband, assuming the positive proband
consents to the release of information to family members.
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It is standard of care to oﬀer prophylactic therapy to all family
members who test positive for the gene mutation and are
identified as being part of a hereditary MTC kindred.

2. Ethical Issues with RET Mutation Screening
In this unique inherited cancer context, genetic testing
remains the only eﬀective route to prevention and treatment
for hereditary MTC [9, 13]. Using the “reasonable person
standard,” a reasonable person who understands and appreciates the benefits of genetic testing for MTC ought to choose
to be tested. Yet this is not always the case. Uptake of this
testing is significantly less than 100% [10–12, 19, 20, 42–
45], indicating that the apparently rational decision is not
being made or that there are barriers to understanding and
appreciating the benefits of genetic testing.
Clearly, significant numbers of at-risk individuals are
not being tested or notified about MTC, which means that
many individuals are not making a reasonable decision about
getting tested and many others are failing to notify family
members.
Unfortunately, the uptake of genetic testing among
relatives of patients with MTC is inadequate and not well
studied. Social and ethical barriers to genetic screening
for MTC may include literacy, education, income, culture/religion, and social/family relationships. The positive
proband may exercise his or her autonomy and decide not
to disclose his/her test results to family members at-risk.
In the United States, the Health Insurance Portability and
Accountability Act (HIPAA) protects a positive proband’s
right to privacy, thereby preventing those at-risk from being
tested. Although some physicians in these circumstances may
choose to breach HIPAA and notify at risk family members,
this is not an option that has been ethically or legally resolved
[46]. Both the decision to test and the decision to disclose
test results to at risk relatives directly impact prevention
of this cancer. Even when results are disclosed to at-risk
relatives, decisions about prophylactic therapy need to be
made. The strained resources of genetic counseling services
and accepted clinical practice suggest that genetic counselors
are largely unavailable to patients with MTC [17, 18, 47–
49]. Even in European countries that oﬀer genetic counseling
free of charge, patients report that genetic counseling is
inadequate and flawed [50–52]. This suggests a profound
misunderstanding of the meaning of genetic test results
for this cancer, as well as covert socioethical barriers to
screening, including inadequate decision-making capacity,
limited access to healthcare, and cultural, religious, and
economic factors. There are no specific guidelines regarding
genetic screening, disclosure of results, or discussion of
results for children with a family history of MTC.
In the one qualitative study that specifically looked at
ethical issues in hereditary MTC, the investigator interviewed members from only one family and reported that
genetic counseling was inadequately delivered [18]. This
same author [17] also interviewed 21 patients who had
thyroidectomies consequent to a hereditary MTC diagnosis
and found that the genetic issues were poorly appreciated.
A nursing study followed MTC patients on an MTC Listserv
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and found serious problems with informed decision-making
[53]. Brauer et al. [20] observed problems in long-term
follow-up data on aﬀected kindreds, suggesting that we know
next to nothing about disclosure patterns among probands
and how information is communicated or filtered by family
members.
These clinical and psychosocial conditions demonstrate
the need to protect vulnerable populations and establish clear
ethical guidelines for MTC screening and management in the
pediatric population.
In addition to the screening issues, barriers ranging from
poor comprehension of the clinical facts to healthcare access
may lead at-risk individuals to refuse life-saving prophylactic
thyroidectomy for themselves or their children.
Since genetic screening involves the dissemination of
complex information, such barriers can seriously interfere
with decisions about testing, disclosure of test results to
family members, and decisions aﬀecting children of families
at risk. There is no guideline regarding whether assent should
be required and, if so, at what age.
More than 50% of index patients with hereditary MTC
present with a thyroid mass, and up to 75% have distant
metastasis [19, 42]; this further suggests that genetic screening practices are currently inadequate. Given that MTC
accounts for roughly 17% of all pediatric thyroid cancers,
the literature reports 15% of aﬀected families that do not
“accept” screening [43], and many gene carriers delay or
refuse prophylactic thyroid surgery for their children [44];
children who are relatives of index patients are at risk of going
undetected. We focus on two ethical issues that aﬀect atrisk children: (1) how we do identify at-risk children with an
RET-positive relative who refuses to disclose that they have the
mutation? (2) How do we protect RET-positive children whose
parents refuse prophylactic thyroidectomy?

3. The Case for Mandated Newborn
Screening for RET
There is a strong ethical justification for mandated newborn
screening for mutations in the RET gene, particularly
when the American Thyroid Association recommends RET
mutation testing in children “shortly after birth” in some
cases, or before the age of 5 in other cases [4]. RET
mutation screening not only meets all of the classical WilsonJungner criteria [54] for mandated newborn screening, but a
much clearer case can be made for this screening test than
some diseases that are already screened for, such as 2-MBG
(2-methylbutyryl-coenzyme A dehydrogenase deficiency),
for which only a “handful of infants have been diagnosed”
with no clear treatment available [55]. Even in PKU, for
which screening identifies 200 aﬀected children annually,
there are not multiple at-risk family members associated with
each positive screen. RET mutation screening in newborns,
on the other hand, can identify large kindreds at risk. One
positive screen can lead to many more individuals at risk in
both pediatric and adult populations. Based on 2007 U.S.
birth rate statistics, as well as the latest SEER data on the
lifetime risk of developing thyroid cancer, we know that,
every year, 36,500 babies are born who will ultimately get
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thyroid cancer. We know that around 8% of these cancers
will be medullary thyroid cancer, meaning that nearly 3000
of the babies born in the USA in 2007 will get medullary
thyroid cancer at some point in their lives. Based on these
statistics, we safely estimate that roughly 1000 newborns in
the USA in 2007 would develop hereditary medullary thyroid
cancer, which could be picked up by a newborn screening
program. Additionally, during the first 20 years of screening,
a newborn screening program has the potential to pick up
significant numbers of at risk older children and adults who
had not been screened as newborns. For example, if we
assume at least 5 unscreened family members at-risk for
each of these 1,000 positive newborn screens we could detect
annually, we may be able to identify and/or prevent 5,000
cases of MTC annually.
The ten criteria proposed by Wilson-Jungner [54] have
been endorsed by the WHO and the President’s Council on
Bioethics [55] for the applicability of any newborn screening
program.
(1) The condition sought should be an important health
problem.
(2) There should be an accepted treatment for patients
with recognized disease.
(3) Facilities for diagnosis and treatment should be
available.
(4) There should be a recognizable latent or early symptomatic stage.
(5) There should be a suitable test or examination.
(6) The test should be acceptable to the population.
(7) The natural history of the condition, including
development from latent to declared disease, should
be adequately understood.
(8) There should be an agreed policy on whom to treat as
patients.
(9) The cost of case finding (including diagnosis and
treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on
medical care as a whole.
(10) Case-finding should be a continuing process and not
a “once and for all” project.
MTC meets all of the above criteria. In the case of
criterion 5, the recommendation for newborn screening is
reasonable because genetic testing can pinpoint an identifiable RET mutation in 95% of persons with MEN 2
syndromes and in 88% of those with FMTC [1, 4, 56].
In addition, about 1%–9% of apparently sporadic cases
will be found to have identifiable RET mutations [4, 56].
Of those individuals found to have an identifiable RET
mutation, 100% will develop MTC without any therapeutic
intervention, although the age of onset will be variable
[1]. Thus, we can prevent MTC in approximately 90% of
at-risk individuals with current genetic testing. Furthermore, genetic counseling and testing of family members of
mutation-positive cases would lead to identification of entire
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aﬀected families that otherwise may have gone undetected.
Thus, one positive newborn screening test that identifies
a RET mutation can lead to prevention of multiple cases
of MTC. As with any screening test, the methodology used
influences the sensitivity of the test. The vast majority of
cases of MEN2 and FMTC are due to mutations aﬀecting
cysteine residues in exons 10 and 11 of the RET gene [1, 56].
However, testing only for mutations aﬀecting the cysteine
residues would miss cases of MEN2 and FMTC caused by
mutations at other sites in the RET gene. While sequencing
of the RET gene would detect these additional cases, it
would also yield a significant number of variants of unknown
clinical significance, which would raise the question of how
to follow individuals in whom such variants were detected,
since no biochemical test exists to confirm the diagnosis of
either MEN2 or FMTC. As with all other newborn screening
tests, it would be necessary to explore the most eﬀective way
of performing RET gene mutation screening before it is put
into practice.
In the case of criterion 9, in the USA, cancer accounts
for $60.9 billion in direct medical costs and $15.5 billion
for indirect morbidity costs [57]. Newborn screening would
directly reduce the costs associated with late diagnosis of
aggressive tumors. In the specific MTC population, the costs
associated with treatment of metastatic disease are closest
to the costs associated with pancreatic cancer, which is the
most expensive cancer cost of the eight cancers evaluated by
Chang et al. [57], at an average cost of $7,282 monthly per
patient. This high cost is related to the fact that no eﬀective
chemotherapy treatments exist for these cancers. Even this
may be an underestimate, since treatment for metastatic
MTC is currently only available as part of costly clinical trials.
The President’s Council on Bioethics endorsed the
original Wilson-Jungner criteria in 2008, highlighting that
this classical criteria would mean the disorder for which
mandated newborn screening is recommended: “must pose
a serious threat to the health of the child, its natural history
must be well understood, and timely and eﬀective treatment
must be available, so that the intervention as a whole is
likely to provide a substantial benefit to the aﬀected child”
[55]. The American Council on Medical Genetics endorses
mandatory newborn screening by stating: “Societies have an
ethical obligation to protect their most vulnerable members,
especially if these people cannot protect themselves. Newborns deserve the special protection aﬀorded by mandatory
screening for disorders where early diagnosis and treatment
favourably aﬀect outcome . . .. The primary purpose of
mandatory newborn screening is to benefit the newborn
through early treatment” [55]. We believe that RET gene
mutation screening rises to this standard.

4. Pediatric Ethics Guidelines
Given the clear benefits of early screening and prophylactic
treatment and the problems with barriers to informed
consent and decision-making in the adult population, we
propose that the decision to have children at risk for
hereditary MTC tested should be removed from the parents
or guardians, who currently frequently elect to decline having

International Journal of Pediatric Endocrinology
their children tested. Instead, we suggest that screening
for the RET mutation testing for hereditary MTC ought
to be implemented into existing state newborn screening
programs and treated similarly to other newborn screening
tests, which include the screening for hypothyroidism.
Implementation of such guidelines will significantly increase
uptake of genetic testing in this population, which in turn
could greatly improve thyroid cancer prevention and reduce
costs associated with the significant morbidity of this cancer.
We further propose ethical guidelines to deal with the older
pediatric population to protect them from unnecessary and
significant harms resulting from poor parental or guardian
decision-making.
4.1. Proposed Ethics Guideline 1: Genetic Screening in Pediatric
Populations. Outside of the newborn screening context
(which allows parents to opt out, but does not explicitly seek
consent), genetic screening in pediatric populations requires
informed consent from a child’s surrogate decision-maker
(parent or guardian). The incidence of parents refusing to
consent to medical procedures or treatment for their children
in a number of pediatric clinical scenarios is well documented [58–60], as are the numerous barriers to informed
consent for complex genetic syndromes. Beneficence-based
obligations support mandatory newborn screening for RET
proto-oncogene mutations. RET mutation screening meets
the ethical criteria for newborn screening proposed by the
President’s Council on Bioethics [55] and the traditional
Wilson-Jungner criteria [54]. Newborn screening removes
decision-making from the surrogate, which is frequently a
barrier to screening in the neonatal population. For screening of older children, consent from the legally authorized
decision-maker would be necessary for screening, but this
would be phased out over time as newborn screening
was universally adopted. Parental refusal to allow screening
may require implementing the recommendation outlined
in Proposed Ethics Guideline 3, depending on the risk of
aggressive MTC developing in childhood, as in situations
where the RET mutation is classified as “ATA-D” [4].
4.2. Proposed Ethics Guideline 2: Disclosure of RET Mutation.
As with newborn screening, positive results should be shared
with a child’s physician and with the child’s legally authorized
decision-makers. Children over the age of 14 should be
included in the disclosure of this information unless a
strong reason exists for excluding them. To mitigate potential
problems with surrogate decision-makers misinforming an
older child, or deciding to withhold the information from
an older child, disclosure of results should be provided in a
family conference that includes, if possible, at least three of
the following experts: a pediatric endocrinologist, surgeon
or oncologist; genetic counselor, social worker, and ethicist.
The disclosure of results may present complex issues for the
family and should be done using a multidisciplinary team
approach.
4.3. Proposed Ethics Guideline 3: Surrogate’s Refusal of Prophylactic Thyroidectomy. In patients where prophylactic thyroidectomy is strongly recommended according to clinical
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practice guidelines [4], surrogates who refuse such surgery
for their children should be assessed for their understanding
and appreciation of the issues, including their rationale
for the refusal. The physician has an obligation to exhaust
eﬀorts to explain and disclose the clinical situation, including
weighing the benefits and risks of delaying thyroidectomy
and using other biochemical markers in children with RET
mutations that carry lower risks, such as those classified
as “ATA-B” and “ATA-A” [4]. In higher-risk scenarios, such
as mutations classified as “ATA-D” [4], every eﬀort should
be made to properly inform and seek permission from the
legally authorized decision-maker, and an ethics consultation
should be obtained. If refusal persists, and harm to the
patient is imminent and foreseeable, beneficent-based moral
obligations require that the practitioner, with the support
of the ethics and legal consultant, seek state intervention
through a court order or the involvement of child protective
services. We believe these cases invoke the Harm Principle
[59] as justification for seeking state intervention when
parents refuse life-saving medical treatment (thyroidectomy)
that carries a good likelihood of preventing significant
harm (i.e., death from thyroid cancer). The Harm Principle,
originally outlined by J. S. Mill, in his On Liberty treatise
(1859) states:
“The only purpose for which power can be rightfully
exercised over any member of a civilized community, against
his will, is to prevent harm to others... The only part
of the conduct of any one, for which (an individual) is
amenable to society, is that which concerns others. In the
part which merely concerns himself, his independence is, of
right, absolute. Over himself, over his own body and mind,
the individual is sovereign.”
The Harm Principle establishes that a competent individual has complete autonomy over his/her own beliefs
and actions so long as those beliefs or actions do not
create a significant likelihood of serious harm to another
person. If one’s actions or decisions place another in
harm’s way, state intervention is justified. In cases where
prophylactic surgery can be delayed until the age of consent,
aggressive follow-up of the patient should include repeated
attempts to discuss prophylactic surgery with the parent or
guardian. In cases where delay of thyroidectomy is likely
to result in disseminated cancer, however, state intervention
should be sought to overturn a parental decision to refuse
thyroidectomy.
4.4. Proposed Ethics Guideline 4: Disclosure of Risk and the
Duty to Warn. In cases where probands have not disclosed
their RET mutation status to their at-risk relatives, the
patient should always be asked permission to disclose. If
permission is denied, an ethics consult should be obtained,
and the patient’s reasons for refusing permission should
be explored. The patient should also be provided with the
option of disclosure without being directly identified. In
cases where refusal of disclosure puts the at-risk relative(s)
in danger of imminent serious harm, the physician must
recognize that there are limits to patient autonomy and
that confidentiality “ends where public peril begins” [61].
The ethical justification and moral imperative for notifying

5
at-risk relatives against patients’ wishes is supported by
“duty to warn” case law precedents [46], as well as the
American Society of Human Genetics Social Issues and
Subcommittee on Familial Disclosure [62]. Known at-risk
relatives should be notified of the risk without specifically
identifying the patient, and privacy laws should be modified
to allow for this. In cases where harm to minors is
imminent, implementation of Ethics Guideline 3 may be
warranted.

5. Conclusions
Hereditary MTC is a diﬀerent clinical context than other
hereditary cancer syndromes (e.g., BRCA1, BRCA2), where
penetrance is significantly lower, the genetic test can yield
ambiguous results, and the eﬀectiveness and perceived benefits of “treatment” is unknown or has significant side eﬀects.
Even with full understanding and appreciation of risk profile,
a range of socioeconomic factors may interfere with one’s
ability or willingness to obtain genetic testing, including
access, counseling, socioeconomic status and location. Other
factors that may interfere with disclosure of test results to atrisk family members include awareness of family members in
situations of half-siblings and adoption, or communication
barriers among family members due to dysfunction or
estrangement.
Hereditary MTC is the only autosomal dominant cancer
with 100% penetrance where genetic screening is the singular pathway to prevention and/or cure, which includes a
treatment without significant morbidity. Suspected socioethical barriers to genetic screening and prophylactic therapy
include inadequate genetic counseling and problems related
to understanding of genetics or risk assessment [47–49, 63,
64]; decision-making capacity problems [65], which may
involve literacy, numeracy, and education levels; access to
healthcare, which may involve income and insurance coverage [45]; family and cultural dynamics [66]; confidentiality
[46, 67]; religious and cultural beliefs; social and community
location. Since genetic screening involves the dissemination
of complex information, such barriers can seriously interfere
with decisions about testing, disclosure of test results to
family members, and decisions about prophylactic surgery.
At-risk children should be protected from preventable
harms associated with metastatic MTC, resulting from either
inadequate or irrational decisions made by their guardians.
These proposed pediatric ethics guidelines seek to mitigate
harms associated with hereditary MTC in the pediatric
population.
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